ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
10.12
+0.50 (+5.20%)
At close: 4:00PM EDT

10.15 +0.03 (0.30%)
After hours: 4:34PM EDT

Stock chart is not supported by your current browser
Previous close9.62
Open9.66
Bid10.01 x 1000
Ask10.18 x 1000
Day's range9.57 - 10.17
52-week range5.42 - 19.70
Volume205,116
Avg. volume278,833
Market cap137.241M
Beta4.88
PE ratio (TTM)N/A
EPS (TTM)-2.79
Earnings date9 Aug 2017 - 14 Aug 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.17
Trade prices are not sourced from all markets
  • MarketWatch9 days ago

    Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

    Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. Zynerba(ZYNE) , which is developing cannabis-based therapies for rare neurospsychiatric disorders, said the trial of ZYN001, which delivers tetrahydrocannabinol (THC) through a transdermal patch, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC in healthy volunteers. THC is the psychoactive ingredient in cannabis and the company was trying to find a way to deliver it without patients having to take it orally, which can make them high.

  • MarketWatch13 days ago

    Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals

    Shares of Zynerba Pharmaceuticals Inc. (zyne) slid about 17% in premarket trade Thursday, after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. The company, which is developing cannabis-based therapies for rare neruospsychiatric disorders, said the trial of ZYN001, a patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC. "This Phase 1 study was a single and multiple dose, placebo-controlled first-in-man study to assess the safety and pharmacokinetics of ZYN001 administered as a transdermal patch to healthy adult subjects," Zynerba said in a statement.

  • The Tech Revolutionizing The Billion Dollar Marijuana Business
    Oilprice.com2 months ago

    The Tech Revolutionizing The Billion Dollar Marijuana Business

    Reefer madness is reaching a full-blown frenzy, with total legal worldwide marijuana sales expected to surpass $63 billion in less than ten years. And now the tech behind bitcoin is poised to take the cannabis boom to the next level

  • Associated Press2 months ago

    Zynerba: 1Q Earnings Snapshot

    The Devon, Pennsylvania-based company said it had a loss of 91 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Daily3 months ago

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.

  • Associated Press4 months ago

    Zynerba reports 4Q loss

    The Devon, Pennsylvania-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Can This Beaten-Down Marijuana Stock Roar Back in 2018?
    Motley Fool7 months ago

    Can This Beaten-Down Marijuana Stock Roar Back in 2018?

    Zynerba faces some big questions heading into the new year.

  • Associated Press8 months ago

    Zynerba reports 3Q loss

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • 3 Marijuana Stocks That Like to Live Life Dangerously
    Motley Fool9 months ago

    3 Marijuana Stocks That Like to Live Life Dangerously

    Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.

  • Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
    Zacks10 months ago

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes